Iterum Therapeutics Q3 EPS $(1.20) Misses $(0.91) Estimate. Cash and equivalents of $35.9M
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics reported Q3 losses of $(1.20) per share, missing the consensus estimate of $(0.91) by 31.87%. This represents a 179.07% increase in losses from the same period last year. The company has $35.9M in cash and equivalents.
November 14, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Iterum Therapeutics missed Q3 EPS estimates by 31.87% and reported a 179.07% increase in losses from the previous year, with $35.9M in cash and equivalents.
The significant miss on earnings per share and the substantial increase in losses year-over-year are likely to negatively impact investor sentiment and the stock price in the short term. The company's financial position, indicated by its cash and equivalents, may provide some cushion, but the earnings miss is a strong negative signal.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100